- Home
- MITQ vs CYCN Comparison
MITQ vs CYCN Comparison
Compare MITQ & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MITQ
- CYCN
- Stock Information
- Founded
- MITQ N/A
- CYCN 2018
- Country
- MITQ United States
- CYCN United States
- Employees
- MITQ N/A
- CYCN N/A
- Industry
- MITQ Telecommunications Equipment
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- MITQ Telecommunications
- CYCN Health Care
- Exchange
- MITQ Nasdaq
- CYCN Nasdaq
- Market Cap
- MITQ 5.5M
- CYCN 6.5M
- IPO Year
- MITQ 2021
- CYCN N/A
- Fundamental
- Price
- MITQ $0.65
- CYCN $2.81
- Analyst Decision
- MITQ
- CYCN
- Analyst Count
- MITQ 0
- CYCN 0
- Target Price
- MITQ N/A
- CYCN N/A
- AVG Volume (30 Days)
- MITQ 9.7M
- CYCN 21.8K
- Earning Date
- MITQ 05-15-2025
- CYCN 08-06-2025
- Dividend Yield
- MITQ N/A
- CYCN N/A
- EPS Growth
- MITQ N/A
- CYCN N/A
- EPS
- MITQ N/A
- CYCN N/A
- Revenue
- MITQ $18,613,000.00
- CYCN $2,081,000.00
- Revenue This Year
- MITQ N/A
- CYCN N/A
- Revenue Next Year
- MITQ N/A
- CYCN N/A
- P/E Ratio
- MITQ N/A
- CYCN N/A
- Revenue Growth
- MITQ N/A
- CYCN N/A
- 52 Week Low
- MITQ $0.50
- CYCN $1.27
- 52 Week High
- MITQ $1.55
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- MITQ 57.86
- CYCN 41.24
- Support Level
- MITQ $0.61
- CYCN $3.02
- Resistance Level
- MITQ $1.10
- CYCN $3.16
- Average True Range (ATR)
- MITQ 0.06
- CYCN 0.21
- MACD
- MITQ 0.01
- CYCN -0.03
- Stochastic Oscillator
- MITQ 29.49
- CYCN 16.26
About MITQ Moving iMage Technologies Inc.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.